The evaluation of these doses was performed in various periods, ranging from 20 weeks to 68 weeks
However, tirzepatide has a dual mode of action, being an agonist for the GIP receptor (Gastric Inhibitory Peptide) as well as for the GLP-1 receptor
( 1 ) Originally approved to treat type 2 diabetes, researchers began creating more targeted versions of GLP-1 medications after it was found that diabetes patients taking the medication often lost weight, sometimes without even intentionally trying
Follow the standard protocols outlined earlier, choosing based on your goals rather than tolerance concerns
Either pathway alters the peptide structure and potentially its biological activity
Dopamine replacement therapy, learning and reward prediction in Parkinson's disease: implications for rehabilitation